Banarian Nordic Res (BVNKF) 17.7568 $BVNKF Bavarian

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Banarian Nordic Res (BVNKF) 17.7568 $BVNKF

Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Thu Mar 27, 4:05AM CDT
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on

Bavarian Nordic Announces 2013 Full Year Results
GlobeNewswire - Wed Mar 19, 2:43AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today published its 2013 annual report. Revenue was DKK 1,213 million / USD 224 million (DKK 1,017 million / USD 188 million in 2012). The Group recorded a profit before tax of DKK 6 million / USD 1 million (DKK 49 million loss / USD 9 million loss in 2012). Revenue and results were in line with the expectations for the year. As planned, the Company delivered 7 million doses of IMVAMUNE(R) to the U.S. in 2013, of which 1.4 million doses relate to the new contract that was entered in April 2013.

Bavarian Nordic to Host Full Year 2013 Results Conference Call
Thomson Reuters ONE - Thu Mar 13, 11:30AM CDT
KVISTGAARD, Denmark - March 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 full year results on Wednesday, March 19, 2014.

Bavarian Nordic's MVA-BN(R) Vaccine Platform Selected by U.S. Department of Defense for New Vaccine Development
GlobeNewswire - Fri Feb 21, 3:25AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its MVA-BN vaccine platform technology has been selected by the Defense Threat Reduction Agency (DTRA), a part of the United States Department of Defense, for the development of a vaccine against two potential biological threats to national security - Burkholderia pseudomallei and Burkholderia mallei.

Bavarian Nordic to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thomson Reuters ONE - Fri Feb 07, 10:30AM CST
KVISTGAARD, Denmark - February 7, 2014 - Bavarian Nordic (OMX: BAVA, OTC: BVNRY) announced today that James Breitmeyer, MD, PhD and Executive Vice President will present at the 16th Annual BIO CEO & Investor Conference in New York City on Monday, February 10, 2014 at 4:30 p.m. ET.

Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
GlobeNewswire - Fri Nov 22, 12:52AM CST
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Health Canada has granted a Notice of Compliance approving IMVAMUNE(R) for active immunization against smallpox in a public health emergency. IMVAMUNE is indicated for persons 18 years of age and older who are contraindicated to replicating smallpox vaccines. This includes individuals with immune deficiencies and skin disorders.

Bavarian Nordic to Present at Jefferies 2013 Global Healthcare Conference in London
Thomson Reuters ONE - Fri Nov 15, 10:31AM CST
KVISTGAARD, Denmark - November 15, 2013 - Bavarian Nordic A/S (OMX: BAVA) announced today that Anders Hedegaard, President & CEO will present at the Jefferies 2013 Global Healthcare Conference in London on Wednesday, November 20, 2013 at 4:20 p.m. GMT.

Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE® Smallpox Vaccine to the U.S. Strategic National Stockpile
PR Newswire - Fri Nov 15, 8:00AM CST
Bavarian Nordic A/S (OMX: BAVA) announced today that it completed the delivery of 20 million doses of IMVAMUNE® smallpox vaccine to the U.S. Strategic National Stockpile (SNS) for use in the event of a smallpox emergency in the U.S.

Bavarian Nordic Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 14, 1:51AM CST
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) today publishes its interim financial results for the first nine months of 2013. Revenue for the period was DKK 875 million (2012: DKK 750 million) and the result before tax was a loss of DKK 18 million (2012: DKK 17 million profit). The Infectious Diseases division remains profitable with an EBIT after internal allocations of DKK 250 million in the period (2012: DKK 221 million). As of September 30, 2013 the cash preparedness was DKK 546 million, including unutilized credit lines of DKK 120 million. The company has research and delivery contracts with the U.S. Government of which payments of up to USD 330 million (approximately DKK 1.8 billion) remain as of September 30, 2013. The company maintains its 2013 full-year expectations with revenues in the level of DKK 1,100 million and a break-even result before tax. The Infectious Diseases division is expected to generate an EBIT of approximately DKK 360 million, which will be offset by total costs of DKK 325 million in the Cancer Immunotherapy division, primarily relating to the global Phase 3 study of PROSTVAC(R). The Group's cash preparedness at year-end is expected to be approximately DKK 600 million.

Bavarian Nordic - Interim Financial Report for the Period 1 January to 30 September 2013
Thomson Reuters ONE - Thu Nov 14, 12:39AM CST
KVISTGAARD, Denmark, November 14, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2013. Revenue for the period was DKK 875 million (2012: DKK 750 million) and the result before tax was a loss of DKK 18 million (2012: DKK 17 million profit). The Infectious Diseases division remains profitable with an EBIT after internal allocations of DKK 250 million in the period (2012: DKK 221 million). As of September 30, 2013 the cash preparedness was DKK 546 million, including unutilized credit lines of DKK 120 million. The company has research and delivery contracts with the U.S. Government of which payments of up to USD 330 million (approximately DKK 1.8 billion) remain as of September 30, 2013. The company maintains its 2013 full-year expectations with revenues in the level of DKK 1,100 million and a break-even result before tax. The Infectious Diseases division is expected to generate an EBIT of approximately DKK 360 million, which will be offset by total costs of DKK 325 million in the Cancer Immunotherapy division, primarily relating to the global Phase 3 study of PROSTVAC®. The Group's cash preparedness at year-end is expected to be approximately DKK 600 million.

Bavarian Nordic to Host Third Quarter 2013 Results Conference Call
Thomson Reuters ONE - Thu Nov 07, 10:31AM CST
KVISTGAARD, Denmark - November 7, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 third quarter results on Thursday, November 14, 2013.

Global Smallpox Clinical Trials Review, H2, 2013
M2 - Tue Oct 15, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xg46m/smallpox_global) has announced the addition of the "Smallpox Global Clinical Trials Review, H2, 2013" report to their offering. Smallpox Global Clinical Trials Review, H2, 2013" provides data on the Smallpox clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Smallpox. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Smallpox. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Smallpox Therapeutics Clinical Trials - Bavarian Nordic A/S - Sanofi - SIGA Technologies, Inc. - Cangene Corporation - Chimerix, Inc. - Sanofi Pasteur, Inc. - VaxGen, Inc. (Inactive) - DynPort Vaccine Company LLC For more information visit http://www.researchandmarkets.com/research/3x...pox_global

Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Bavarian Nordic Reports Financial Results for the First Half of 2013
GlobeNewswire - Thu Aug 22, 1:51AM CDT
Bavarian Nordic A/S (OMX:BAVA) today publishes its results for the first half of 2013. Revenue for the period was DKK 556 million (2012: DKK 445 million) and the result before tax was a loss of DKK 43 million (2012: DKK 13 million loss). The Infectious Disease division remains profitable with an EBIT after internal allocations of DKK 131 million in the period (2012: DKK 116 million). As of June 30, 2013 the cash preparedness was DKK 695 million, including unutilized credit lines of DKK 120 million. The company has research and delivery contracts with the U.S. Government of which payments of up to USD 384 million (approximately DKK 2.1 billion) remain as of June 30, 2013. The company maintains its 2013 full-year expectations with revenues in the level of DKK 1,100 million and a break-even result before tax. The cash preparedness at year-end is expected to be roughly DKK 600 million.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Magnetron Solutions for Peak RF Performance

Updated Category News Views 129

Revolutionizing RF Power with Advanced Magnetron Transmitters In the realm of radio frequency (RF) technology, Diversified Technologies, Inc. (DTI) has unveiled a groundbreaking solid-state magnetron transmitter, which utilizes a novel Marx modulator. This innovative approach allows users to finely tune the pulse wave, enhancing overall performance and adaptability for...

Continue Reading
Lineage Inc. Strengthens Financial Agreements and Growth Potential

Updated Category News Views 142

Lineage Inc. Updates Financial Agreements for Greater Flexibility Lineage, Inc., a real estate investment trust recognized for its expertise in logistics, has made important changes to its financial agreements to bolster its financial standing. By adding more subsidiaries as obligors, the company demonstrates its flexibility and growth strategy. Recently, Lineage grabbed...

Continue Reading
Super League Achieves Major Financial Milestones in 2025

Updated Category News Views 394

Super League Reports Impressive Financial Growth Super League has recently showcased remarkable financial improvements, marking a significant turnaround in its operations. This comes on the heels of the company achieving a robust balance sheet powered by strategic investments, including a $20 million private placement and, notably, having zero debt. These developments not...

Continue Reading
Michael Lachmann's 'Spacetime Capsule' Documentary Now Streaming

Updated Category News Views 241

Michael Lachmann's Innovative Documentary Series The new documentary series, Spacetime Capsule, directed by British filmmaker Michael Lachmann, has recently premiered on popular Chinese video platforms. This captivating series, produced by China Review Studio, consists of three episodes that creatively employ the concept of a "spacetime capsule" to frame its narrative,...

Continue Reading
Innovative Leaders of Tomorrow: The 2025 TIME100 Next List

Updated Category News Views 395

TIME Introduces the Inspiring 2025 TIME100 Next List Tate McRae to Perform at the Upcoming TIME100 Next Event In a recent announcement, TIME has unveiled its exciting 2025 TIME100 Next list, spotlighting a diverse group of 100 emerging leaders from across the globe. These individuals are not only shaping the future but are also redefining leadership norms within their...

Continue Reading